ABXL, also known as Abraxas BioScience, is a biopharmaceutical company focused on the development of innovative therapies for serious medical conditions. The company's pipeline consists of proprietary drug candidates aimed at treating diseases with high unmet medical needs, leveraging advanced technologies in drug discovery and development. With a commitment to scientific excellence and regulatory compliance, ABXL is positioned to make significant contributions to the healthcare landscape. Its collaborative approach with academia and industry partners enhances its potential for creating transformative treatments that address critical patient needs.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |